Advanced search
Publication Cover
Modern Rheumatology Volume 18, 2008 - Issue 6
Journal homepage
24
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study

Akiko SudaDepartment of Rheumatology, Yokohama Minami Kyosai Hospital, 1-21-1 Mutsuurahigashi, Kanazawa-ku, Yokohama, Kanagawa 236-0037, Japan;Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, JapanCorrespondence[email protected]
,
Shouhei NagaokaDepartment of Rheumatology, Yokohama Minami Kyosai Hospital, 1-21-1 Mutsuurahigashi, Kanazawa-ku, Yokohama, Kanagawa 236-0037, Japan
,
Shigeru OhonoDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
,
Haruko IdeguchiDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
,
Takayoshi SogaDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
&
Yoshiaki IshigatsuboDepartment of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
Pages 609-614 | Received 26 Mar 2008, Accepted 05 Jun 2008, Published online: 02 Jan 2014

References

  • Abe C. Clinical evaluation of immunomodulators. Int J. Immun-other. 1985;1:7–10.
  • Kashiwazaki S, Shiokawa Y. Bucillamine: a new immunomod-ulator. Int J. Immunother. 1987;3:1–6.
  • Nagashima M, Shu G, Yamamoto K, Yamahatsu S, Yoshino S. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. Epidemiology of DMARDs treatment in Japan. Cfin Exp Rheu-matol. 2005;23(1):27–35.
  • Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol. 2006;16(6):376–80.
  • Mimori T. Anti-rheumatic drugs. In: Ochi T, Yamamoto K, Ryuu J, editors. Manual of diagnosis and guideline for treatment of RA. Tokyo: Japanese rheumatism foundation; 2004. pp. 84–98. (in Japanese).
  • Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323–8.
  • Hirohata S, Lipsky PE. Regulation of B cell function by bucill-amine, a novel disease-modifying antirheumatic drug. Clin Immunol Immunopathol. 1993;66(1):43–51.
  • Tsuji F, Seki I, Aono H, Odani N, Mizutani K, Okamoto M, et al. Bucillamine mechanism inhibiting IL—lbeta-induced VEGF production from fibroblast-like synoviocytes. Int Immunophar-macol. 2007;7(12):1569–76.
  • Suematsu A, Tajiri Y, Nakashima T, Taka J, Ochi S, Oda H, et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol. 2007;17(1):17–23.
  • Morabito L, Montesinos MC, Schreibman DM, Baiter L, Thompson LF, Resta R, et al. Methotrexate and sulfasala-zine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998;101:295–300.
  • Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156:1937–41.
  • Haagsma CJ, Russel FG, Vree TB, Van Riel PL, Van de Putte LB. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and rela-tionship to clinical response. Br J Clin Pharmacol. 1996;42(2): 195–200.
  • Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheu-matoid arthritis: a randomized, controlled, double-blind 52-week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58(4):220–5.
  • Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifica-tion of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
  • van Riel PLCM, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 2000;59\(suppl 1):i28–31.
  • Yokota N, Kuga Y, Kanazawa T, Morishita M, Tanida K, Itou K. Ten years results of bucillamine in the treatment of rheumatoid arthritis. Mod Rheumatol. 2007;17(1):33–6.
  • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, con-trolled trial. Arthritis Rheum. 2005;52(11):3381–90.
  • Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a sys-tematic retrospective study of 709 patients. Rheumatology (Oxford). 2007;46(2):327–34.
  • Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125–33.
  • Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol. 2006;16(2): 85–91.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.